High Potency VEGFRs/MET/FMS Triple Blockade by TAS-115 Concomitantly Suppresses Tumor Progression and Bone Destruction in Tumor-Induced Bone Disease Model with Lung Carcinoma Cells

CSF-1/CSF-1R targeting agents in clinical development for cancer therapy

(2015) Carola H Ries et al.   CURRENT OPINION IN PHARMACOLOGY

CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study

(2015) Philippe A Cassier et al.   LANCET ONCOLOGY

Targeting IL-34 in chronic inflammation

(2014) Emma L. Masteller et al.   DRUG DISCOVERY TODAY

Prospective Study on the Incidence of Bone Metastasis (BM) and Skeletal-Related Events (SREs) in Patients (pts) with Stage IIIB and IV Lung Cancer—CSP-HOR 13

(2014) Nobuyuki Katakami et al.   Journal of Thoracic Oncology

Colony-stimulating factor 1 potentiates lung cancer bone metastasis

(2014) Jaclyn Y Hung et al.   LABORATORY INVESTIGATION

Matriptase and MET are prominently expressed at the site of bone metastasis in renal cell carcinoma: immunohistochemical analysis

(2014) Shoichiro Mukai et al.   Human Cell

Analysis of Stromal Cell Secretomes Reveals a Critical Role for Stromal Cell–Derived Hepatocyte Growth Factor and Fibronectin in Angiogenesis

(2013) Andrew C. Newman et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Determinants of Survival in Advanced Non–Small-Cell Lung Cancer in the Era of Targeted Therapies

(2013) Joshua Bauml et al.   Clinical Lung Cancer

The Novel VEGF Receptor/MET-Targeted Kinase Inhibitor TAS-115 Has Marked In Vivo Antitumor Properties and a Favorable Tolerability Profile

(2013) H. Fujita et al.   MOLECULAR CANCER THERAPEUTICS

Osteoclasts: New Insights

(2013) Feng Xu et al.   Bone Research

Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial

(2012) David C. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

VEGF, FLT3 ligand, PlGF and HGF can substitute for M-CSF to induce human osteoclast formation: implications for giant cell tumour pathobiology

(2012) Richard M Taylor et al.   LABORATORY INVESTIGATION

FMS Kinase Inhibitors: Current Status and Future Prospects

(2012) Mohammed I. El-Gamal et al.   MEDICINAL RESEARCH REVIEWS

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

(2011) Karim Fizazi et al.   LANCET

Breast Cancer-Derived Bone Metastasis Can Be Effectively Reduced through Specific c-MET Inhibitor Tivantinib (ARQ 197) and shRNA c-MET Knockdown

(2011) S. Previdi et al.   MOLECULAR CANCER THERAPEUTICS

VEGF165 Promotes the Osteolytic Bone Destruction of Ewing's Sarcoma Tumors by Upregulating RANKL

(2009) Hui Guan et al.   ONCOLOGY RESEARCH

VEGF enhancement of osteoclast survival and bone resorption involves VEGF receptor-2 signaling and β3-integrin

(2008) Q YANG et al.   MATRIX BIOLOGY